JP2011530309A5 - - Google Patents

Download PDF

Info

Publication number
JP2011530309A5
JP2011530309A5 JP2011523001A JP2011523001A JP2011530309A5 JP 2011530309 A5 JP2011530309 A5 JP 2011530309A5 JP 2011523001 A JP2011523001 A JP 2011523001A JP 2011523001 A JP2011523001 A JP 2011523001A JP 2011530309 A5 JP2011530309 A5 JP 2011530309A5
Authority
JP
Japan
Prior art keywords
nucleic acid
mammal
polypeptide
protein
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530309A (ja
Filing date
Publication date
Priority claimed from US12/192,015 external-priority patent/US7951377B2/en
Application filed filed Critical
Publication of JP2011530309A publication Critical patent/JP2011530309A/ja
Publication of JP2011530309A5 publication Critical patent/JP2011530309A5/ja
Pending legal-status Critical Current

Links

JP2011523001A 2008-08-14 2009-08-14 多価ワクチン Pending JP2011530309A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/192,015 2008-08-14
US12/192,015 US7951377B2 (en) 2005-08-23 2008-08-14 Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
PCT/US2009/004664 WO2010019262A2 (en) 2008-08-14 2009-08-14 Polyvalent vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014120307A Division JP2014207910A (ja) 2008-08-14 2014-06-11 多価ワクチン

Publications (2)

Publication Number Publication Date
JP2011530309A JP2011530309A (ja) 2011-12-22
JP2011530309A5 true JP2011530309A5 (OSRAM) 2012-10-04

Family

ID=41669535

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011523001A Pending JP2011530309A (ja) 2008-08-14 2009-08-14 多価ワクチン
JP2014120307A Pending JP2014207910A (ja) 2008-08-14 2014-06-11 多価ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014120307A Pending JP2014207910A (ja) 2008-08-14 2014-06-11 多価ワクチン

Country Status (9)

Country Link
US (6) US7951377B2 (OSRAM)
EP (2) EP3178842B1 (OSRAM)
JP (2) JP2011530309A (OSRAM)
CN (1) CN102177175A (OSRAM)
AU (1) AU2009282442B2 (OSRAM)
BR (1) BRPI0917205A2 (OSRAM)
CA (1) CA2733898C (OSRAM)
IL (1) IL211184B (OSRAM)
WO (1) WO2010019262A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
WO2007024941A2 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
BRPI0921588B1 (pt) 2008-11-18 2021-12-28 Beth Israel Deaconess Medical Center Vacina compreendendo um polipeptídeo viral e seu método de preparação, kit e uso do polipeptídeo viral
EP2739300B1 (en) 2011-07-05 2019-06-19 Duke University N-terminal deleted gp120 immunogens
EP2763699A4 (en) 2011-10-03 2015-05-20 Univ Duke VACCINE
WO2014093901A1 (en) 2012-12-13 2014-06-19 Baylor Research Institute At Dallas Triheptanoin for the treatment of glucose transporter 1 deficiency
ES2957209T3 (es) * 2013-09-30 2024-01-15 Triad Nat Security Llc Polipéptidos inmunogénicos mosaicos del VIH de región conservada
WO2015057950A1 (en) * 2013-10-16 2015-04-23 New England Biolabs, Inc. Reverse transcriptase with enhanced properties
EP3119890A4 (en) 2014-03-19 2017-12-27 Duke University Swarm immunization with envelopes from ch505
AU2015236147A1 (en) * 2014-03-25 2016-10-13 Duke University Mosaic HIV-1 sequences and uses thereof
US10322141B2 (en) 2014-03-31 2019-06-18 Duke University Compositions comprising CH848 envelopes and uses thereof
US10232034B2 (en) 2014-09-28 2019-03-19 Duke University Compositions comprising CH505 envelopes, and trimers
EP3423472A4 (en) 2016-03-01 2019-12-25 Duke University COMPOSITIONS WITH HIV COVERS FOR INDUCING CH235 CELL LINE ANTIBODIES
WO2017152146A2 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
WO2018067580A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
EP3526236B1 (en) * 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
EP3630174A4 (en) 2017-05-25 2021-07-07 Duke University MODIFIED COMPOSITIONS CONTAINING HIV ENVELOPE PROTEINS
EP3860650A4 (en) 2018-10-01 2022-06-29 Duke University Hiv-1 envelope stabilizing mutations
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
AU2022207422A1 (en) 2021-01-14 2023-07-27 Gilead Sciences, Inc. Hiv vaccines and methods of using

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6503753B1 (en) 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7655774B2 (en) * 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
US20040115621A1 (en) * 2000-02-18 2004-06-17 Allen Rodrigo Ancestral viruses and vaccines
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CA2466050A1 (en) 2001-11-07 2003-05-15 Duke University Polyvalent immunogen
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
ATE520708T1 (de) 2003-03-28 2011-09-15 Us Gov Health & Human Serv Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
WO2005034992A2 (en) 2003-09-15 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv vaccines based on env of multiple clades of hif
CA2918585C (en) * 2003-09-17 2019-05-21 Duke University Consensus/ancestral immunogens
WO2005035555A1 (en) * 2003-10-10 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies
WO2007024941A2 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
EP1954309A2 (en) 2005-10-17 2008-08-13 Novartis AG Multiclade hiv vaccines
US20130273103A1 (en) 2010-09-28 2013-10-17 Los Alamos National Security, Llc Polyvalent immunogen

Similar Documents

Publication Publication Date Title
JP2011530309A5 (OSRAM)
JP2011136997A5 (OSRAM)
JP2011155981A5 (OSRAM)
JP2012126742A5 (OSRAM)
JP2013172734A5 (OSRAM)
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2010227108A5 (OSRAM)
JP2017048194A5 (OSRAM)
JP2012095652A5 (OSRAM)
JP2013539361A5 (OSRAM)
JP2015524422A5 (OSRAM)
JP2019530462A5 (OSRAM)
JP2014503206A5 (OSRAM)
JP2014012688A5 (OSRAM)
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
WO2006063101A3 (en) Vaccines for the rapid response to pandemic avian influenza
WO2007147529A3 (en) Recombinant viral vaccine
JP2010088434A5 (OSRAM)
WO2010138263A3 (en) Novel aav 's and uses thereof
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
JP2011528896A5 (OSRAM)
WO2011008956A3 (en) Mammalian genes involved in infection
WO2010134939A3 (en) Mammalian genes involved in infection
JP2014525439A5 (OSRAM)
WO2013052859A3 (en) Adenoviral vector-based respiratory syncytial virus (rsv) vaccine